Literature DB >> 25809622

Complications of serogroup B meningococcal disease in survivors: a review.

Fereshteh Dastouri, Ahmad Mirmohammad Hosseini, Elizabeth Haworth, Gulam Khandaker, Harunor Rashid, Robert Booy1.   

Abstract

This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25809622     DOI: 10.2174/1871526515999150320155614

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  4 in total

1.  Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak.

Authors:  Blair Capitano; Krista Dillon; Andre LeDuc; Bruce Atkinson; Cynthia Burman
Journal:  Hum Vaccin Immunother       Date:  2019-01-08       Impact factor: 3.452

2.  Metagenomic data from cerebrospinal fluid permits tracing the origin and spread of Neisseria meningitidis CC4821 in China.

Authors:  Hongbin Chen; Mei Li; Shangyu Tu; Xiaoyang Zhang; Xiaojuan Wang; Yawei Zhang; Chunjiang Zhao; Yinghui Guo; Hui Wang
Journal:  Commun Biol       Date:  2022-08-18

Review 3.  Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Authors:  Robert G K Donald; Julio Cesar Hawkins; Li Hao; Paul Liberator; Thomas R Jones; Shannon L Harris; John L Perez; Joseph J Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2016-12-14       Impact factor: 3.452

4.  Study protocol: The Dutch 20|30 Postmeningitis study: a cross-sectional follow-up of two historical childhood bacterial meningitis cohorts on long-term outcomes.

Authors:  O El Tahir; R C J de Jonge; S Ouburg; S A Morré; A M van Furth
Journal:  BMC Pediatr       Date:  2019-12-30       Impact factor: 2.125

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.